The AIRCARE project, funded by the Horizon Europe program, involving leading European universities, research institutes, hospitals, medical technology companies with the mission to revolutionize the diagnosis and treatment of upper airway tumours (UADT).
The AIRCARE consortium includes twelve partners from six countries. The project is coordinated by the Italian Institute of Technology. Key participants include the Fondazione Istituto Italiano di Tecnologia (Italy), KU Leuven (Belgium), Syddansk Universitet (Denmark), Scuola Superiore Sant’Anna (Italy), Università degli Studi di Genova and San Martino Hospital (Italy), IDIBAPS (Hospital Clínic de Barcelona, Spain), El.En. SpA (Italy), BARCO NV (Belgium), ACMIT Gmbh (Austria), Inventya Ventures (Ireland), TimeLex (Belgium), and Università degli Studi “Gabriele d’Annunzio” (Italy).
The aim of the project is to introduce advanced AI-driven and robotic technologies into clinical workflows, setting new standards in the detection, diagnosis and treatment of UADT cancers.
AIRCARE is developing an AI-powered Integrated Diagnostic System for real-time detection and diagnosis. This innovative system facilitates early detection and provides in situ cancer characterization, eliminating the need for biopsies and lengthy histopathology analyses, thus streamlining the diagnostic process and accelerating patient care.
AIRCARE will introduce an Integrated Therapy System, transforming the surgical setup into a robotic system for enhanced recognition of tumour margins, increased surgical precision. This system comprises AI-assisted tumour segmentation, robotic laser steering and advanced robotic forceps, all controlled by an ergonomic console to support the surgeon in complex procedures with greater safety and accuracy.
ACMIT is a proud partner of this project. ACMIT’s area of responsibility lies on the one hand in integrating the individual input elements into a central surgeon console and on the other hand in overseeing the entire development regarding regulatory compliance and development documentation for a subsequent seamless certification process.
AIRCARE aims to validate the technologies via clinical trials and support their adoption as the next standard of care in Ear, Nose and Throat (ENT) cancer centres.
For more information, please visit:
